| Schedule of business acquisitions, by acquisition |
Stock issuances in relation to acquisitions during the years ended December 31, 2024, 2023, and 2022 were as follows: | | | | | | | | | | | | | | | | | | | | | (In thousands, except for per share data) | | Period of Acquisition | | Shares Issued | | Fair Value of Shares Issued | | OmicEra | | May 2022 | | 265,186 | | $ | 14,792 | |
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following: | | | | | | | | | | (In thousands) | | | | Cash | | $ | 52,527 | | | Fair value of replaced equity awards | | 1,675 | | | Total purchase price | | $ | 54,202 | |
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following: | | | | | | | | | | (In thousands) | | | | Common stock issued | | $ | 14,792 | | | Contingent consideration | | 4,600 | | | Cash paid related to working capital adjustment | | 16 | | | Total purchase price | | $ | 19,408 | |
|
| Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI) |
The amount recognized in AOCI for the years ended December 31, 2024, 2023 and 2022 were as follows: | | | | | | | | | | | | | | | | | | | | | | (In thousands) | | Cumulative Translation Adjustment | | Unrealized Gain (Loss) on Securities (1) | | AOCI | Balance at January 1, 2022 | | $ | 23 | | | $ | (1,466) | | | $ | (1,443) | | Other comprehensive income (loss) before reclassifications | | 30 | | | (4,049) | | | (4,019) | | Amounts reclassified from accumulated other comprehensive income (loss) | | — | | | 226 | | | 226 | | | Net current period change in accumulated other comprehensive loss | | 30 | | | (3,823) | | | (3,793) | | | Balance at December 31, 2022 | | $ | 53 | | | $ | (5,289) | | | $ | (5,236) | | | Other comprehensive income (loss) before reclassifications | | 1,321 | | | 1,416 | | | 2,737 | | Amounts reclassified from accumulated other comprehensive income (loss) | | — | | | 3,927 | | | 3,927 | | | Net current period change in accumulated other comprehensive loss | | 1,321 | | | 5,343 | | | 6,664 | | | Balance at December 31, 2023 | | $ | 1,374 | | | $ | 54 | | | $ | 1,428 | | | Other comprehensive income (loss) before reclassifications | | (3,294) | | | 873 | | | (2,421) | | Amounts reclassified from accumulated other comprehensive income (loss) | | — | | | 49 | | | 49 | | Net current period change in accumulated other comprehensive income (loss) | | (3,294) | | | 922 | | | (2,372) | | | Balance at December 31, 2024 | | $ | (1,920) | | | $ | 976 | | | $ | (944) | |
_________________________________ (1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2024, 2023, and 2022. The unrealized gain (loss) recorded on available-for-sale securities is a non-cash investing activity.
|
| Schedule of amounts reclassified from accumulated other comprehensive income (loss) |
Amounts reclassified from AOCI for the years ended December 31, 2024, 2023, and 2022 were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | Details about AOCI Components (In thousands) | | Affected Line Item in the
Statements of Operations | | 2024 | | 2023 | | 2022 | | Change in value of available-for-sale investments | | | | | | | | | | Sales and maturities of available-for-sale investments | | Investment income (loss) | | $ | 49 | | | $ | 3,927 | | | $ | 226 | | | Total reclassifications | | | | $ | 49 | | | $ | 3,927 | | | $ | 226 | |
|